Weight Loss

Tesamorelin

GHRH analog FDA-approved for visceral fat reduction. Clinical data to 52 weeks. Targets deep abdominal fat specifically while optimizing GH. The most evidence-backed fat-targeting peptide.

12-26+ weeks
2mg/day
First effects: Weeks 1-4
SubQ daily

Interactive Timeline

GH/IGF-1
Visceral Fat
Subcutaneous Fat
Sleep/Recovery
Energy/Anti-Aging
Weeks 1-4
Weeks 5-8
Weeks 9-16
Weeks 17-26
52 weeks

Tap dots for details. Scroll horizontally to see full timeline.

Weeks 1-4

GH Signaling

  • GH pathway activating
  • Sleep improving
  • Foundation being laid

Fat loss didn't show until week 10 but then was unmistakable.

Weeks 5-8

Early Mobilization

  • Fat mobilization beginning
  • Belt on next notch
  • Scale may not move much

Belt on next notch. Scale barely moved.

Weeks 9-16

Measurable Reduction

  • 2 inch waist typical
  • Visceral fat targeting
  • Body composition changing

Week 12, waist down 2 inches. Nothing else changed.

Weeks 17-26

Peak Results

  • Maximum fat reduction
  • Deep belly fat specifically
  • Sustained protocol

More visceral-specific than anything I've used. The deep belly fat.

Dosing Protocol

2mg SubQ daily. Do not combine with CJC/Ipa (both stimulate GH).

All timelines reflect community-reported observations. Not medical advice. Individual results vary. Consult a qualified healthcare provider before starting any peptide protocol.

DYK Peptides

Community-reported peptide data